Research programme: tumour necrosis factor-alpha secretion inhibitors - Biokine

Drug Profile

Research programme: tumour necrosis factor-alpha secretion inhibitors - Biokine

Alternative Names: BKT-104; BTT-1507

Latest Information Update: 16 Aug 2005

Price : $50

At a glance

  • Originator Biokine Therapeutics
  • Developer Biotie Therapies Corp.
  • Class
  • Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 12 Aug 2005 Discontinued - Preclinical for Psoriasis in Israel (PO)
  • 12 Jan 2005 Preclinical trials in Psoriasis in Israel (PO)
  • 12 Jan 2005 BKT 104 has been licensed to BioTie Therapies worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top